Sotagliflozin is a drug being developed to lower blood sugar levels in type 1 diabetes by increasing the amount of sugars excreted in the urine. It is taken once a day tablet in conjunction with insulin to prevent large rises and falls in blood sugar levels. This may be especially useful for people who cannot control their blood sugar levels with insulin alone. Sotagliflozin is currently in clinical trials which have shown that sotagliflozin has the potential to reduce and control blood sugar levels when taken with insulin.
LY-900014 (ultra-rapid lispro) is in development for the treatment of adult patients with type 1 diabetes mellitus. Type 1 diabetes mellitus is a condition which usually starts early in life and occurs as a result of the pancreas not producing enough (or sometimes any) insulin. This results in elevated blood sugar levels which can damage many organs in the body. Type 1 diabetes usually runs in families. While type 1 diabetes cannot be cured, having regular, at least daily, injections of insulin can keep blood sugar levels stable. However some people, despite having regular injections of insulin, still do not have stable blood sugar levels.